Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2019 2
2020 2
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

8 results
Results by year
Filters applied: . Clear all
Page 1
Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma.
Lozano E, Mena MP, Díaz T, Martin-Antonio B, León S, Rodríguez-Lobato LG, Oliver-Caldés A, Cibeira MT, Bladé J, Prat A, Rosiñol L, Fernández de Larrea C. Lozano E, et al. Among authors: oliver caldes a. Clin Cancer Res. 2020 Sep 1;26(17):4688-4698. doi: 10.1158/1078-0432.CCR-19-3673. Epub 2020 Jun 8. Clin Cancer Res. 2020. PMID: 32513837 Free article.
Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.
Bataller A, Oñate G, Diaz-Beyá M, Guijarro F, Garrido A, Vives S, Tormo M, Arnan M, Salamero O, Sampol A, Coll R, Vall-Llovera F, Oliver-Caldés A, López-Guerra M, Pratcorona M, Zamora L, Villamon E, Roué G, Blanco A, Nomdedeu JF, Colomer D, Brunet S, Sierra J, Esteve J; Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias (CETLAM). Bataller A, et al. Among authors: oliver caldes a. Br J Haematol. 2020 Oct;191(1):52-61. doi: 10.1111/bjh.16857. Epub 2020 Jun 8. Br J Haematol. 2020. PMID: 32510599 Clinical Trial.
Early T-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness.
Bataller A, Garrote M, Oliver-Caldés A, López-Guerra M, Colomer D, Aymerich M, Camós M, Vega-García N, Díaz-Beyá M, Esteve J. Bataller A, et al. Among authors: oliver caldes a. Br J Haematol. 2019 May;185(4):755-757. doi: 10.1111/bjh.15601. Epub 2018 Oct 18. Br J Haematol. 2019. PMID: 30334573 No abstract available.
Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy.
Moreno DF, Pereira A, Tovar N, Cibeira MT, Magnano L, Rozman M, López-Guerra M, Colomer D, Martín-Antonio B, Jiménez-Segura R, Isola I, Rodríguez-Lobato LG, Oliver-Caldés A, Mena MP, Rosiñol L, Bladé J, Fernández de Larrea C. Moreno DF, et al. Among authors: oliver caldes a. Cancers (Basel). 2021 Apr 23;13(9):2055. doi: 10.3390/cancers13092055. Cancers (Basel). 2021. PMID: 33922804 Free PMC article.
Immunoparesis defined by heavy/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease.
Isola I, Moreno DF, Moga E, Mena MP, Tovar N, Rodríguez-Lobato LG, Oliver-Caldés A, Salgado MC, Brasó-Maristany F, Yagüe J, Cibeira MT, Prat A, Rosiñol L, Bladé J, Fernández de Larrea C. Isola I, et al. Among authors: oliver caldes a. Ann Hematol. 2021 Aug 31. doi: 10.1007/s00277-021-04653-2. Online ahead of print. Ann Hematol. 2021. PMID: 34463804